IDEAYA Biosciences (IDYA) Receivables - Net (2020 - 2026)

IDEAYA Biosciences (IDYA) posted Receivables - Net of $6.6 million for Q1 2026, up 9.83% sequentially from $6.0 million in Q4 2025.

IDEAYA Biosciences (IDYA) Receivables - Net (2020 - 2026) Analysis & Trends

IDEAYA Biosciences has reported Receivables - Net for 7 years, with the latest figure at $6.6 million in Q1 2026.

Quarterly Receivables - Net changed N/A year-over-year to $6.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.6 million (changed N/A YoY) and the FY2025 annual result came in at $6.0 million, up 199000.0% from the prior year.
Receivables - Net grew to $6.6 million in Q1 2026 per IDYA's latest filing, from $6.0 million in the prior quarter.
Over five years, Receivables - Net peaked at $6.7 million in Q3 2023 and troughed at $1000.0 in Q2 2024.
A 5-year average of $1.8 million and a median of $244000.0 in 2022 frame the typical range for Receivables - Net.
The sharpest annual moves came in 2024 and 2025: Receivables - Net plunged 99.7% in 2024, then jumped 199000.0% in 2025.
Over 5 years, Receivables - Net stood at $200000.0 in 2022, then plunged by 91.0% to $18000.0 in 2023, then plunged by 83.33% to $3000.0 in 2024, then surged by 199000.0% to $6.0 million in 2025, then climbed by 9.83% to $6.6 million in 2026.
According to Business Quant data, Receivables - Net over the past three periods registered $6.6 million, $6.0 million, and $3000.0 for Q1 2026, Q4 2025, and Q4 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	IDEAYA Biosciences	3.50 Bn	2.67 Bn	-

Download Data